JMIR Research Protocols (Jan 2021)

Mobile Health Intervention to Close the Guidelines-To-Practice Gap in Hypertension Treatment: Protocol for the mGlide Randomized Controlled Trial

  • Lakshminarayan, Kamakshi,
  • Murray, Thomas A,
  • Westberg, Sarah M,
  • Connett, John,
  • Overton, Val,
  • Nyman, John A,
  • Culhane-Pera, Kathleen A,
  • Pergament, Shannon L,
  • Drawz, Paul,
  • Vollbrecht, Emily,
  • Xiong, Txia,
  • Everson-Rose, Susan A

DOI
https://doi.org/10.2196/25424
Journal volume & issue
Vol. 10, no. 1
p. e25424

Abstract

Read online

BackgroundSuboptimal treatment of hypertension remains a widespread problem, particularly among minorities and socioeconomically disadvantaged groups. We present a health system–based intervention with diverse patient populations using readily available smartphone technology. This intervention is designed to empower patients and create partnerships between patients and their provider team to promote hypertension control. ObjectiveThe mGlide randomized controlled trial is a National Institutes of Health–funded study, evaluating whether a mobile health (mHealth)-based intervention that is an active partnership between interprofessional health care teams and patients results in better hypertension control rates than a state-of-clinical care comparison. MethodsWe are recruiting 450 participants including stroke survivors and primary care patients with elevated cardiovascular disease risk from diverse health systems. These systems include an acute stroke service (n=100), an academic medical center (n=150), and community medical centers including Federally Qualified Health Centers serving low-income and minority (Latino, Hmong, African American, Somali) patients (n=200). The primary aim tests the clinical effectiveness of the 6-month mHealth intervention versus standard of care. Secondary aims evaluate sustained hypertension control rates at 12 months; describe provider experiences of system usability and satisfaction; examine patient experiences, including medication adherence and medication use self-efficacy, self-rated health and quality of life, and adverse event rates; and complete a cost-effectiveness analysis. ResultsTo date, we have randomized 107 participants (54 intervention, 53 control). ConclusionsThis study will provide evidence for whether a readily available mHealth care model is better than state-of-clinical care for bridging the guideline-to-practice gap in hypertension treatment in health systems serving diverse patient populations. Trial RegistrationClinicaltrials.gov NCT03612271; https://clinicaltrials.gov/ct2/show/NCT03612271 International Registered Report Identifier (IRRID)DERR1-10.2196/25424